US2002004528A1PendingUtilityA1

Method for the treatment of insomnia

Priority: Jul 9, 1998Filed: Aug 3, 2001Published: Jan 10, 2002
Est. expiryJul 9, 2018(expired)· nominal 20-yr term from priority
A61P 25/08A61P 25/20A61K 31/195A61K 31/197A61K 31/00
39
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The instant invention is a method of using certain analogs of glutamic acid and gamma-aminobutyric acid to treat insomnia.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A method for treating a mammal suffering from insomnia comprising administering to said mammal a pharmaceutical composition comprising an effective amount of a GABA analog.  
     
     
         2 . The method according to  claim 1 , wherein the GABA analog is the compound according to Formula I:  
       
         
           
           
               
               
           
         
       
       wherein R 1  is hydrogen or lower alkyl and n is an integer of from 4 to 6, and the pharmaceutically acceptable salts thereof.  
     
     
         3 . The method according to  claim 2 , wherein Formula I comprises gabapentin.  
     
     
         4 . The method according to  claim 2 , comprising from about 10 mg to about 400 mg of Formula I.  
     
     
         5 . The method according to  claim 3 , comprising from about 10 mg to about 400 mg of gabapentin.  
     
     
         6 . The method according to  claim 1 , wherein the GABA analog is a compound according to Formula II:  
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof wherein 
 R 1  is a straight or branched alkyl of from 1 to 6 carbon atoms, phenyl, or cycloalkyl of from 3 to 6 carbon atoms;  
 R 2  is hydrogen or methyl; and  
 R 3  is hydrogen, methyl, or carboxyl;  
 
     
     
         7 . The method according to claim  11 , wherein Formula II comprises pregabalin.  
     
     
         8 . The method according to claim  11 , comprising from about 0.15 mg to about 65 mg of Formula II.  
     
     
         9 . The method according to claim  12 , comprising from about 0.15 mg to about 65 mg of pregabalin.

Join the waitlist — get patent alerts

Track US2002004528A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.